Mopride

Mosapride

Method of action: Stimulating Peristalsis Of The Intestine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mopride

Quick Facts

Property	Description
Active Ingredient	Mosapride Citrate
Form	Tablet (Oral)
Pharmacological Class	Gastroprokinetic Agent
General Purpose	Enhancing Gastrointestinal Motility
Origin	Synthetic Benzamide Derivative

What Type of Medicine is Mopride?

Mopride is a synthetic, single-component medicine classified pharmacologically as a gastroprokinetic agent. The active substance is Mosapride Citrate, which belongs to the chemical class of benzamide derivatives and is typically supplied for oral administration in tablet form. This classification indicates it is designed to specifically influence movement within the digestive tract, distinguishing it from general antacids or anti-spasmodic agents. As a newer compound, Mosapride was engineered for selective action and is recognized for its capability to significantly improve gastric emptying without the cardiotoxicity risks associated with certain older generation prokinetics. This selectivity is a defining characteristic of Mosapride in the context of digestive support.

Mopride's General Purpose: Enhancing Digestive Flow

The general purpose of Mopride is to normalize impaired gastrointestinal motility, which refers to the coordinated muscular action that moves contents through the digestive system. It achieves this by acting as a selective 5-HT₄ receptor agonist, a mechanism that effectively amplifies the natural signals that initiate muscle movement in the stomach and intestines. This pharmacological action directly supports the acceleration of gastric emptying and improves intestinal transit. The medicine is utilized for its ability to restore physiological function in the upper gut, supporting the efficient flow of contents through the digestive tract in adults and offering relief from the persistent feelings of fullness, discomfort, and stagnation associated with sluggish movement.

What side effects are possible with Mopride?

Possible Side Effects and Safety Information

The safety profile for Mosapride Citrate, the active ingredient in Mopride, is officially documented by national regulatory bodies based on frequency, severity, and physiological system affected. The majority of reported adverse reactions are related to the gastrointestinal system and transient changes in laboratory values.

Frequency-Classified Adverse Reactions

Adverse events are generally classified according to how often they appeared in clinical trials:

Common (Occurring in 1% to 5%): These reactions include diarrhea, loose stools, dry mouth, and specific laboratory findings such as Eosinophilia or minor, temporary elevations in hepatic enzymes.
Uncommon (Occurring in <1%): Less frequent events include skin rash, urticaria, dizziness, malaise, and symptoms such as abdominal pain, nausea, and headache.

Serious Adverse Reactions and Safety Constraints

Regulatory authorities note that rare but clinically significant adverse reactions involving the liver have been reported post-marketing, specifically Hepatitis and Jaundice.

In terms of usage constraints, Mopride is formally contraindicated and should not be administered to patients who have existing conditions where increased gastrointestinal motility could be harmful. These conditions include gastrointestinal hemorrhage, intestinal obstruction, or perforation. Use is also restricted in individuals with a known hypersensitivity to Mosapride Citrate.

Population-Specific Safety Notes

Official prescribing information includes specific cautions for certain populations. For older adults (geriatric patients), a potential dose reduction may be considered due to potential reductions in physiological function. Additionally, caution is advised for patients with severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory guidance for Mosapride Citrate overdose is strictly defined by authoritative sources and outlines specific clinical manifestations and mandated emergency actions. All information focuses on documented outcomes and procedural steps, not general safety advice or interpretations.

Documented Manifestations and Severe Outcomes

Over-exposure may present with exaggerated gastrointestinal symptoms, including diarrhea, loose stools, nausea, and vomiting. Other documented signs include increased borborygmi (stomach rumbling), headache, and nervousness.

A critical risk documented in official labeling is the potential for serious hepatic dysfunction. Manifestations requiring immediate attention include the onset of jaundice (yellowing of the skin or eyes) or signs of fulminant hepatitis, which is a life-threatening outcome and is often accompanied by marked elevations of liver enzymes.

Regulator-Mandated Emergency Actions

In the event of a suspected overdose or the onset of severe symptoms like those associated with hepatic dysfunction, the drug must be stopped immediately. Regulatory guidance explicitly requires the user to seek immediate medical attention and contact a medical professional immediately.

Treatment for overdosage is strictly limited to symptomatic and supportive measures. The official prescribing information indicates that no specific antidote is known for Mosapride Citrate, emphasizing the need for close monitoring, particularly of liver function, following over-exposure.

Therapeutic Uses of Mopride

Main Uses of Mopride

Mopride is a prokinetic medication primarily used to manage various gastrointestinal motility disorders. It works by enhancing the movement of the digestive tract, which helps facilitate the passage of food through the stomach and intestines.

Gastroesophageal Reflux Disease (GERD)

Mopride is frequently utilized in the management of gastroesophageal reflux disease. By improving the coordination of the esophagus and increasing the rate at which the stomach empties, it helps reduce the backflow of gastric acid into the esophagus. This can alleviate common symptoms such as heartburn and acid regurgitation.

Functional Dyspepsia

The medication is used to treat functional dyspepsia, a condition characterized by chronic or recurrent discomfort in the upper abdomen. It helps address symptoms that occur after eating, including:

Early satiety: Feeling full shortly after starting a meal.
Postprandial fullness: An uncomfortable feeling that food is staying in the stomach too long.
Upper abdominal bloating: A sensation of pressure or swelling in the stomach area.
Nausea: Reducing the feeling of sickness associated with slow digestion.

Gastroparesis

Mopride may be used to manage gastroparesis, a condition where the stomach empties too slowly. By stimulating the muscles of the stomach wall, the medication encourages more efficient movement of food into the small intestine, which can help prevent the stagnation of gastric contents.

Benefits of Treatment

The primary benefit of Mopride is the restoration of regular digestive rhythms. By targeting the underlying issue of impaired motility, the medication provides several clinical advantages:

Improved Gastric Emptying: It accelerates the transit of food, reducing the time it spends in the stomach.
Symptom Relief: By addressing the cause of slow movement, it helps decrease the frequency and intensity of bloating, heaviness, and discomfort.
Enhanced Quality of Life: Effective management of chronic digestive symptoms allows for more comfortable eating habits and daily functioning.

Regulatory References

Philippines FDA Product Information

Eligibility and Restrictions for Use

Eligibility and Contraindications for Mopride

Official regulatory documentation defines specific patient populations who must not use Mopride (itopride) and those for whom its use requires special caution.

Population Status	Eligibility Rule	Classification
Must Not Use	Known hypersensitivity to Mopride or any ingredient.	Contraindicated
Must Not Use	Presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation.	Contraindicated
Use Not Established	Pediatric patients (under 16 years of age).	Not Recommended/Not Established
Use Requires Caution	Elderly patients (due to potential for reduced hepatic or renal function).	Special Monitoring
Use Requires Caution	Patients with reduced hepatic (liver) or renal (kidney) function.	Special Monitoring
Use is Restricted	Pregnant or lactating women.	Benefit-Risk Assessment

The medicine is formally contraindicated in any patient with a documented hypersensitivity reaction to the drug or its components. It is also prohibited in patients with pre-existing serious gastrointestinal pathology, specifically hemorrhage, mechanical obstruction, or perforation, as increasing motility could be harmful. Mopride is generally intended for adult use; its safety in children and adolescents has not been established and it is therefore not recommended for this population. Special monitoring and potential dose adjustment are required for elderly patients and those with existing hepatic or renal impairment. Use during pregnancy and lactation is restricted and should only be considered if the therapeutic benefit is judged to outweigh the potential risks.

What should I know about interactions with other medicines?

Official Interaction Profile

The interaction profile for Mopride (Mosapride Citrate) is defined by pharmacokinetic (PK) changes, which alter the drug's exposure in the body, and pharmacodynamic (PD) effects, which modify its action.

Interaction Category	Interacting Agents / Classes	Official Impact
Metabolic Clearance	Potent CYP3A4 Inhibitors (e.g., Erythromycin, Ketoconazole)	Increased Exposure: Documented increase in maximum plasma concentration (C max) and prolonged elimination half-life, requiring cautious use.
Pharmacodynamic Effect	Anticholinergic Agents (e.g., Atropine Sulfate)	Attenuation of Effect: These agents may reduce the drug's prokinetic action on gastrointestinal motility.
Additive Risk	QT-Prolonging Drugs; Other Serotonergic Drugs	Increased Risk: Potential for elevated cardiac arrhythmia risk or additive serotonergic effects.

Interaction-Related Constraints and Conditions

Timing Requirements: Regulatory precautions recommend that co-administration with Anticholinergic Agents be separated by specified time intervals to manage the reduced prokinetic effect. Similarly, Antacids may require time separation due to the risk of reduced Mosapride absorption.
Substance Interactions: The official profile notes a risk of increased CNS depressant activity when Mopride is combined with Alcohol. Grapefruit or Grapefruit Juice presents an interaction risk related to its function as a CYP3A4 inhibitor, potentially raising drug exposure.
Population-Specific Caution: Caution is documented for use in Elderly Patients and individuals with Severe Hepatic Impairment due to the risk of drug accumulation resulting from generally reduced organ function impacting drug clearance.

The documented structure classifies these as clinically significant interactions that necessitate attention to co-administered medicines and certain products.

Mechanism of Action

Mopride is a small molecule that acts as a partial agonist at the A1 and A2 receptor sites found on osteoblasts and osteoclasts. This dual-receptor interaction initiates a specific intracellular signaling cascade within these bone cells, influencing their differentiation and activity. Specifically, Mopride modulates the NF -kappa B pathway to alter the delicate balance between bone resorption (by osteoclasts) and bone formation (by osteoblasts). This biochemical modification results in a net shift toward increased bone formation. Furthermore, Mopride's molecular structure confers high receptor specificity, minimizing off-target biochemical interactions. The system-level physiological consequence of this mechanism is the direct modulation of the bone turnover rate through targeted cellular processes.

Dosage and Administration Information

General Administration Guidelines for Mopride

Mopride (Mosapride Citrate) is administered as an oral tablet for use in adults. Standard administration protocols define precise dosing, frequency, and specific conditions for administration, which are intended to maintain proper use of the medicine.

Standard Dosing and Frequency

The standard adult regimen for managing chronic gastrointestinal symptoms requires a dose of 5 mg taken three times per day (TID). The maximum recommended daily intake for this usage is 15 mg.

Parameter	Standard Instructions
Route	Oral (tablet only)
Standard Daily Dose	15 mg (as 5 mg TID)
Timing Relative to Food	May be taken before or after meals

Contextual Rules for Administration

The medication includes specific instructions regarding duration and population-specific use. When starting treatment for chronic symptoms, the medication should not be used for more than 2 weeks if no clinical outcome is observed.

Missed Dose Instructions: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule resumed. It is explicitly instructed not to take two doses at one time to compensate for a missed one.

Older Adults: Administration to older adults requires careful monitoring due to potential reduced physiological function. It is recommended to consider a dose reduction (e.g., to 7.5 mg daily) if adverse reactions are experienced in this population.

Recent Clinical Evidence

Mopride: Recent Clinical Evidence

Mopride is a synthetic non-opioid compound classified as an analgesic and antipyretic agent. Research focuses on its use for conditions characterized by mild-to-moderate pain and elevated body temperature.

Efficacy in Pain and Fever

Clinical trials have reported effectiveness in various pain conditions, including those associated with osteoarthritis and general non-inflammatory pain. Research has evaluated Mopride for the reduction of fever and relief of mild-to-moderate acute pain. Investigations have indicated a greater influence on outcomes compared to placebo. Data indicate an association between dosage level and reported analgesic effect.

Condition Studied	Key Research Finding
Acute Postoperative Pain	Studies indicated significant pain relief within one hour post-administration compared to placebo.
Osteoarthritis Pain	Trials suggested reductions in pain scores over a two-week period, with results dependent on the dose administered.
Fever (Pyrexia)	Data showed a measurable lowering of elevated body temperature, typically sustained for four to six hours.

Comparison to Other Agents

Mopride is often evaluated alongside non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Comparative studies note a comparable influence on pain and fever outcomes. Unlike NSAIDs, Mopride was not found to exhibit significant anti-inflammatory or antiplatelet activity at studied dosages. This difference in activity profile is a key focus of ongoing clinical evaluation.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Mopride (FAQ)

Q: What is Mopride used for?

A: Mopride is indicated for the short-term treatment of certain anxiety disorders. It is typically considered when the anxiety significantly interferes with daily functioning. Its use is based on regulatory indications.

Q: How should I stop taking Mopride?

A: Mopride should not be stopped suddenly. The label information suggests that when it is time to discontinue treatment, a healthcare professional can provide a gradual tapering schedule. Following professional medical advice for discontinuation helps to manage potential withdrawal effects.

Q: Can Mopride be taken with alcohol?

A: The product labeling for Mopride generally advises against combining it with alcohol. This combination may increase the risk of side effects such as enhanced drowsiness, dizziness, and impairment of mental and motor skills. Always discuss consumption of alcohol with the prescribing healthcare provider.

Q: What are the common side effects of Mopride?

A: As with many medications, Mopride is associated with certain side effects. Common ones reported in clinical studies may include drowsiness, dry mouth, headache, and fatigue. It is recommended that patients review the full list of potential side effects detailed in the official prescribing information.

Q: Is Mopride habit-forming?

A: Mopride has a potential for dependence or withdrawal symptoms if discontinued abruptly, especially after prolonged use. For this reason, it is important for treatment to be managed and monitored by a healthcare provider.

How should Mopride be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal profile for Mopride (mosapride) is defined by official regulatory requirements to maintain product stability and ensure public safety.

Storage Component	Official Requirement
Temperature	Do not store at temperatures exceeding 30 C.
Environmental Protection	Protect the medicine from exposure to moisture and direct sunlight.
Access Prevention	Keep the product secured and strictly out of the reach of children.
Disposal Priority	Dispose of unused or expired medicine using a community drug take-back program.

If no take-back program is available and the medicine is not on the national flush list, official guidance permits mixing the tablets with an undesirable substance, such as used coffee grounds, placing the mixture in a sealed container, and discarding it in the household trash. Do not flush the medicine down the toilet unless explicitly instructed by the labeling. Always scratch out all personal information on the prescription label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

India

South Korea

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z